Schizophrenia and Aging: Myths and Reality

Dilip V. Jeste, M.D. Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University of California, San Diego & VA San Diego Healthcare System

Self-Assessment Question 1 Which of the following statements is true?

- A. Rate of age-related cognitive decline in late onset schizophrenic psychoses does not differ from that in normal subjects.
- B. Remission of late onset schizophrenia appears independent of age or chronicity.
- C. Positive symptoms in late onset schizophrenia are as prevalent as in early onset schizophrenia.
- D. Female gender is over-represented among late onset schizophrenics.
- E. All of the above

<u>Compared to early onset schizophrenia, which</u> <u>of the following is true of late onset</u> <u>schizophrenia?</u>

- A. Negative symptoms are more severe
- B. Paranoid subtype is more prevalent
- C. A smaller percentage of patients have ever been married
- D. All of the above
- E. None of the above

Which of the following statements is true of neuropsychological findings in late onset schizophrenics?

- A. A wide range of cognitive deficits have been detected
- B. Compared to early onset schizophrenics, greater deficits in learning and executive functions characterize late onset schizophrenics.
- C. The overall pattern of deficits is similar to those seen in early onset schizophrenia
- D. All of the above
- E. None of the above

Which of the following is true regarding treatment of late onset schizophrenia?

- A. The cumulative incidence of TD with conventional antipsychotics is low in elderly patients.
- B. Risperidone has been shown superior to olanzapine in treating positive and negative symptoms of late onset schizophrenia.
- C. Cognitive Behavioral Social Skills Training has been shown to reduce delusions and hallucinations.
- D. All of the above
- E. None of the above

Which of the following are possible long-term adverse effects of atypical antipsychotics?

- A. Weight gain
- B. Type 2 diabetes mellitus
- C. Hyperlipidemia
- D. Increase in strokes or overall mortality
- E. Any of the above

Major Points


- Schizophrenia or schizophrenia-like psychosis can begin after age 40 (late onset) and even after 60 (very late onset) and follow a relatively stable course
- Course is characterized by persistence of negative symptoms, absence of abnormal cognitive decline, and modest improvement of positive symptoms
- Differential diagnosis includes psychosis of dementia or of other medical conditions, substance use, mood disorders, delusional disorder, psychosis NOS
- Treatment with atypical antipsychotics is associated with potentially hazardous metabolic side effects and increase in mortality rate offset by lower rates of TD and other EPS.
- Psychosocial approaches have been shown to improve functioning and insight but not other symptoms of late onset schizophrenia.

OUTLINE

Introduction

- Course of Schizophrenia in Late Life
- Middle-Age-Onset Schizophrenia
- Very Late-Onset Schizophrenia-like Psychosis
- Pharmacologic & Psychosocial Treatments

Estimated Numbers of People with Psychiatric Disorders in USA



Jeste et al., Arch Gen Psychiatry, 1999

UCSD Studies of Late-Life Schizophrenia

- Over 500 middle-aged and elderly patients with schizophrenia and related psychoses, and over 150 normal comparison subjects
- Longitudinal follow-up with comprehensive clinical, neuropsychological, and functional evaluations


Course of Schizophrenia in Late Life

- Relatively stable and non-deteriorating course
- Negative symptoms persist while positive symptoms show a modest improvement
- The rate of age-related cognitive decline is similar in patients and normal subjects

Jeste DV et al., Acta Psychiatrica Scand, 2003

Correlations with Age in Schizophrenia Patients Aged 40-85 (N=192)

Positive Symptoms:	SAPS	-0.19*
Negative Symptoms:	SANS	-0.15
Daily Neuroleptic Dose:		-0.31**
Cognitive Impairment:	DRS	0.21*
*p<0.05; **p<0.01		



Zorrilla E, et al., Am J. Psychiatry, 2000

Remission of Schizophrenia: Earlier Studies

- Reported rates of remission or recovery range from 3% to 68%
- Variable use and definitions of terms: Cure, Recovery, Remission
- Bias in sample selection
- Inconsistent diagnostic criteria for schizophrenia
- Subjective evaluations

UCSD Criteria for Sustained Remission

- Met DSM-IV criteria for schizophrenia in past, but not currently;
- No hospitalization for last 5 years;
- Living independently; and
- Neuroleptic-free or on low dose of an antipsychotic

Remission Study Conclusions

- 8% of the older schizophrenia patients living in the community met criteria for persistent symptomatic remission
- Remitted patients had somewhat impaired cognition & functioning suggesting that remission in schizophrenia may reflect a return to pre-morbid functioning rather than to "normal level"
- Remission was not related to age or chronicity

Late-Onset Schizophrenia: <u>A Controversial Entity</u>

Age of onset and diagnosis of schizophrenia in USA:

DSM-III (1980) DSM-III-R (1987) DSM-IV (1994)

European terminology:

Paranoia Paraphrenia Late paraphrenia

Questions

- 1. Can schizophrenia manifest after age 45? *If it can,*
- 2. Why do these patients develop schizophrenia?

and

3. What protects them from developing schizophrenia until late in life?

Diagnosis

DSM-III-R or DSM-IV diagnosis with SCID

Age of onset of prodromal symptoms of schizophrenia


Specific inclusion and exclusion criteria

Diagnostic stability over follow-up period


Patient Characteristics

	Early-Onset Schizophrenia (EOS) (N=253)	Middle-Age Onset Schizophrenia (MAOS) (N=65)
Age of onset of schizophrenia	25 (7)	51 (8)
Duration of illness	31 (11)	10 (8)
Neuroleptic dose (mg CPZE/day)	250	126 * 20

SAPS Subscale Scores



Palmer B, et al., Harvard Review of Psychiatry, 2001




MAOS: Similarities with EOS

(I) Clinical

- 1) Severity of positive symptoms
- 2) Family history of schizophrenia
- 3) Minor physical anomalies
- 4) Childhood maladjustment
- 5) Sensory impairment

Age of Onset of Schizophrenia by Gender (Age > 45)



MAOS: Differences from EOS

(I) Clinical

- 1) More common in women
- 2) Less severe negative symptoms
- 3) Mostly paranoid subtype
- 4) Greater % of patients ever married


Psychosocial Factors

- Premorbid Functioning: Suboptimal without being grossly psychopathological;
 Premorbid personality may show paranoid or schizoid traits but not disorder.
- <u>Psychosocial Stressors</u>: Retirement, bereavement, financial loss, physical disability, etc. may serve as precipitants and/or maintainers of psychosis.


Neuropsychological Assessment

- Expanded Halstead-Reitan battery, Age-, gender-, and education-corrected, T-, and deficit-scores for 7 ability areas:
- 1) Verbal, 2) Attention, 3) Psychomotor,
- 4) Memory (retention), 5) Learning,
- 6) Motor, and 7) Abstraction.


Neuropsychological Deficit Scores



Neuropsychological Deficit Scores



MAOS (N=29) vs. Alzheimer Disease (N=61): Longitudinal Study of Mattis' Dementia Rating Scale (DRS)



MAOS: Similarities with EOS

(II) Neuropsychological

- (1) Overall pattern of cognitive impairment
- (III) MRI
 - (1) Nonspecific MRI abnormalities
- (IV) Course & Treatment
 - (1) Chronic Course
 - (2) Qualitative response to neuroleptics
 - (3) Increased mortality

MAOS: Differences from EOS

(II) Neuropsychological

(1) Less severe impairment in learning and in abstraction

(III) MRI

(1) Larger thalamus?

(IV) Course & Treatment

(1) Need for lower doses of neuroleptics

Jeste et al., Am J Psychiatry, 1995; Am J Geriatric Psychiatry, 1997

Very Late-Onset Schizophrenia-like Psychosis

Heterogeneous group of disorders:

- Psychosis of dementia
- Psychosis secondary to general medical conditions or substance use
- Mood disorder with psychotic features
- Delusional disorder
- Psychosis NOS


International Consensus Statement on Late-Onset Schizophrenia

In terms of epidemiology, symptomatology, and identified pathophysiology, LOS (onset after age 40) and very late-onset schizophrenia-like psychosis (onset after age 60) have face validity and clinical utility.

-Howard, Rabins, Seeman, Jeste, and International LOS Group (representatives from Australia, Brazil, Canada, Denmark, France, India, Japan, Spain, Switzerland, UK and USA)

American Journal of Psychiatry, 2000

Cumulative Incidence of TD with Conventional Antipsychotics



Kane et al., J Clin Psychopharm, 1988; Jeste et al., Am J Geriat Psychiatry, 1998


<u>Risperidone vs Olanzapine in</u> <u>Elderly Schizophrenia Pts.</u>

- International, double-blind, 8-week RCT*
- 176 patients, aged >60 years
- Schizophrenia or schizoaffective disorder
- Randomly assigned to flexible doses of Risperidone (1-3; median 2 mg/d) or Olanzapine (5-20; median 10 mg/d)


Risperidone Vs. Olanzapine

- Both atypical antipsychotics produced significant improvement from baseline scores on PANSS
- No significant difference between the 2 drugs on Psychopathology, Cognitive function, QTc, or Reports of EPS or anticholinergic side effects
 - Greater weight gain with olanzapine (p=.05)

TD Incidence in Older Patients: Haloperidol versus Risperidone (1mg/d)



<u>Cumulative Incidence of Definitive TD in Older</u> <u>Patients With Borderline Dyskinesia</u>



40

Atypical Antipsychotics: Possible Long-Term Side Effects

- Weight gain
- Type 2 diabetes mellitus
- Hyperlipidemia
- Hyperprolactinemia
- Cardiac conduction disorders
- Strokes?
- Increased mortality?

FDA Warnings About Antipsychotic Use

In all age groups: Weight gain, Diabetes, Hyperlipidemia

In dementia patients: Strokes, and Mortality

Caution in Interpreting Data on Strokes & Mortality with Antipsychotics

- The patients in these trials were typically 80+ years old, and had multiple risk factors for strokes and mortality
 - No cause- and-effect relationship between the antipsychotics and these adverse events in individual patients has so far been clearly established
 - The exact underlying mechanisms are not yet known

Recommended Dosages in Older Patients (mg/day)

Drug	Initial	Typical Range
Clozapine	6.25-12.5	50-150
Risperidone	0.25-0.5	1-3
Olanzapine	2.5-5	5-15
Quetiapine	12.5-25	75-200

Other Atypical Antipsychotics

Ziprasidone Aripiprazole Others

<u>Cognitive Behavioral,</u> Social Skills Training (CBSST)

Three modules, each with 4 weekly sessions, to be repeated, for a total of 24 group sessions

- **CBT** Thought challenging
- **SST Asking for support**
- **CBSST Solving problems**

Manualized treatment, with homework assignment after "classes"

Randomized Controlled Trial of CBSST

76 Patients with schizophrenia or schizoaffective disorder randomized to CBSST or Tx as usual

Blind assessments on Independent Living Skills Survey, Beck's Cognitive Insight Scale, Comprehensive Module Test for CBSST skills, and Psychopathology (PANSS, HAM-D) at baseline, 3 months, & 6 months

Granholm E, et al., American Jr. of Psychiatry, 2005

CBSST Outcomes

- 86% Patients stayed in treatment
- No significant change in medication management
- Significant improvement at 3 & 6 months on: Mastery of CBSST skills
 Frequency of social activities
 Cognitive insight
 But not on psychopathology

Treatment - Summary

- Atypical antipsychotics have a considerably lower risk of EPS and TD than conventional neuroleptics, but they have other adverse effects
- Medications need to be supplemented by psychosocial therapies

Suggested Readings

- Jeste DV, Symonds LL, Harris MJ, et al.: Nondementia non-praecox dementia praecox?: Lateonset schizophrenia. Am J Geriat Psychiatry 5:302-317, 1997
- Howard R, Rabins P, Seeman MV, et al.: Lateonset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. Am J Psychiatry,157:172-178, 2000
- Jeste DV, Twamley EW, Eyler Zorrilla LT, Golshan S, Patterson TL and Palmer BW: Aging and outcome in schizophrenia. Acta Psychiatrica Scandinavica 107: 336-343, 2003

Self-Assessment Question 1 Which of the following statements is true?

- A. Rate of age-related cognitive decline in late onset schizophrenic psychoses does not differ from that in normal subjects.
- B. Remission of late onset schizophrenia appears independent of age or chronicity.
- C. Positive symptoms in late onset schizophrenia are as prevalent as in early onset schizophrenia.
- D. Female gender is over-represented among late onset schizophrenics.
- E. All of the above

<u>Compared to early onset schizophrenia, which</u> <u>of the following is true of late onset</u> <u>schizophrenia?</u>

- A. Negative symptoms are more severe
- B. Paranoid subtype is more prevalent
- C. A smaller percentage of patients have ever been married
- D. All of the above
- E. None of the above

Which of the following statements is true of neuropsychological findings in late onset schizophrenics?

- A. A wide range of cognitive deficits have been detected
- B. Compared to early onset schizophrenics, greater deficits in learning and executive functions characterize late onset schizophrenics.
- C. The overall pattern of deficits is similar to those seen in early onset schizophrenia
- D. All of the above
- E. None of the above

Which of the following is true regarding treatment of late onset schizophrenia?

- A. The cumulative incidence of TD with conventional antipsychotics is low in elderly patients.
- B. Risperidone has been shown superior to olanzapine in treating positive and negative symptoms of late onset schizophrenia.
- C. Cognitive Behavioral Social Skills Training has been shown to reduce delusions and hallucinations.
- D. All of the above
- E. None of the above

Which of the following are possible long-term adverse effects of atypical antipsychotics?

- A. Weight gain
- B. Type 2 diabetes mellitus
- C. Hyperlipidemia
- D. Increase in strokes or overall mortality
- E. Any of the above

Answers to Self-Assessment Questions

